A carregar...
Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with ALK mutation
Inflammatory myofibroblastic tumor (IMT), a rare sarcoma, is primarily treated via resection of the mass. However, in cases of recurrence or unresectable tumors, no standard care exists. While crizotinib, an anaplastic lymphoma kinase (ALK) inhibitor, is only approved for non-small-cell lung cancer...
Na minha lista:
| Publicado no: | Intern Med |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
The Japanese Society of Internal Medicine
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6478978/ https://ncbi.nlm.nih.gov/pubmed/30449794 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2169/internalmedicine.1640-18 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|